

CITATION REPORT

List of articles citing

Potential Benefits of Muscarinic M3 Receptor Selectivity

DOI: 10.1016/s1569-9056(02)00045-3
European Urology Supplements, 2002, 1, 23-28.

Source: <https://exaly.com/paper-pdf/34229735/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 57 | Antimuscarinics for treatment of overactive bladder. <i>Lancet Neurology, The</i> , 2004 , 3, 46-53 | 24.1 | 334 |
| 56 | Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. <i>European Urology</i> , 2004 , 45, 420-9; discussion 429 | 10.2 | 192 |
| 55 | Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 1493-500 | 5.9 | 28 |
| 54 | QT and QTc interval with standard and suprathreshold doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 1038-47 | 2.9 | 47 |
| 53 | An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. <i>BJU International</i> , 2005 , 95, 580-6 | 5.6 | 83 |
| 52 | A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. <i>BJU International</i> , 2005 , 95, 993-1001 | 5.6 | 116 |
| 51 | Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. <i>BJU International</i> , 2005 , 96, 1055-62 | 5.6 | 51 |
| 50 | Darifenacin in the treatment of overactive bladder. <i>International Journal of Clinical Practice</i> , 2005 , 59, 831-8 | 2.9 | 7 |
| 49 | Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. <i>European Urology</i> , 2005 , 48, 102-9 | 10.2 | 35 |
| 48 | Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. <i>European Urology</i> , 2005 , 48, 471-7 | 10.2 | 65 |
| 47 | Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. <i>World Journal of Urology</i> , 2005 , 23, 248-52 | 4 | 72 |
| 46 | Muscarinic receptor subtype pharmacology and physiology. <i>Progress in Medicinal Chemistry</i> , 2005 , 43, 105-36 | 7.3 | 161 |
| 45 | Increased warning time with darifenacin: a new concept in the management of urinary urgency. <i>Journal of Urology</i> , 2005 , 173, 1214-8 | 2.5 | 59 |
| 44 | Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. <i>Urologic Clinics of North America</i> , 2006 , 33, 465-73, viii | 2.9 | 21 |
| 43 | The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 509-27 | 4 | 6 |
| 42 | In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. <i>Life Sciences</i> , 2006 , 80, 127-32 | 6.8 | 24 |
| 41 | Trospium chloride: a different anticholinergic. <i>Expert Review of Obstetrics and Gynecology</i> , 2006 , 1, 29-39 | | 1 |

| | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 40 | Darifenacin: a selective M3 muscarinic receptor antagonist for the treatment of overactive bladder. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 723-732 | | 1 |
| 39 | Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. <i>BJU International</i> , 2006 , 98, 1025-32 | 5.6 | 48 |
| 38 | The contemporary pharmacological management of overactive bladder. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2006 , 113, 19-28 | 3.7 | 3 |
| 37 | Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. <i>International Urogynecology Journal</i> , 2006 , 17, 239-47 | 2 | 49 |
| 36 | Urinary incontinence: economic burden and new choices in pharmaceutical treatment. <i>Advances in Therapy</i> , 2006 , 23, 556-73 | 4.1 | 32 |
| 35 | Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. <i>European Urology</i> , 2006 , 50, 317-26 | 10.2 | 192 |
| 34 | Darifenacin for the treatment of overactive bladder. <i>Aging Health</i> , 2007 , 3, 143-147 | | |
| 33 | Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. <i>Cochrane Database of Systematic Reviews</i> , 2007 , CD003190 | | 13 |
| 32 | Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2697-704 | 2.5 | 27 |
| 31 | Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 511-23 | 4 | 21 |
| 30 | Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. <i>The Cochrane Library</i> , 2007 , CD003190 | 5.2 | 23 |
| 29 | Darifenacin treatment of patients \geq 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2347-58 | 2.5 | 75 |
| 28 | Development and validation of bioanalytical methods for imidafenacin (KRP-197/ONO-8025) and its metabolites in human urine by using liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2007 , 21, 940-8 | 1.7 | 10 |
| 27 | [Pharmacological and clinical profile of imidafenacin developed as a new therapeutic agent for overactive bladder]. <i>Folia Pharmacologica Japonica</i> , 2008 , 131, 379-87 | 0 | 1 |
| 26 | Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction. <i>Advances in Urology</i> , 2009 , 345324 | 1.6 | 8 |
| 25 | In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. <i>British Journal of Pharmacology</i> , 2009 , 156, 807-17 | 8.6 | 13 |
| 24 | Ratiometric Ca ²⁺ measurement in human recombinant muscarinic receptor subtypes using the Flexstation scanning fluorometer. <i>Journal of Receptor and Signal Transduction Research</i> , 2009 , 29, 100-6 | 2.6 | 6 |
| 23 | Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder. <i>Urological Science</i> , 2010 , 21, 38-43 | 0.3 | 3 |

| | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 22 | Urinary incontinence: pharmacotherapy options. <i>Annals of Medicine</i> , 2011 , 43, 461-76 | 1.5 | 25 |
| 21 | Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity. <i>International Urogynecology Journal</i> , 2011 , 22, 907-17 | 2 | 21 |
| 20 | Contemporary management of overactive bladder. <i>Postgraduate Medicine</i> , 2012 , 124, 104-16 | 3.7 | 1 |
| 19 | Clinical trials and overactive bladder: lessons learned. <i>Clinical Investigation</i> , 2012 , 2, 689-705 | | |
| 18 | Anticholinergics for overactive bladder therapy: central nervous system effects. <i>CNS Neuroscience and Therapeutics</i> , 2012 , 18, 167-74 | 6.8 | 70 |
| 17 | A New Solvent System (Cyclopentyl Methyl Ether/Water) in Process Development of Darifenacin HBr. <i>Organic Process Research and Development</i> , 2012 , 16, 1591-1597 | 3.9 | 6 |
| 16 | Antimuscarinic therapy [what is new?]. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2012 , 9, e21-e25 | | 1 |
| 15 | Antimuscarinic drugs for overactive bladder. 2013 , 24-37 | | |
| 14 | Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. <i>Pharmacology & Therapeutics</i> , 2018 , 189, 130-148 | 13.9 | 44 |
| 13 | Rooibos (<i>Aspalathus linearis</i>) extract, containing eriodictyol-6-C- β -glucoside as the active component, stimulates exocrine glands via the M3 muscarinic acetylcholine receptor. <i>Journal of Functional Foods</i> , 2019 , 55, 248-254 | 5.1 | 3 |
| 12 | Antimuscarinic Pharmacotherapy for Overactive Bladder. 2019 , 85-113 | | |
| 11 | Study of the pharmacokinetics of eriodictyol-6-C- β -glucoside, a flavonoid of rooibos (<i>Aspalathus linearis</i>) extract, after its oral administration in mice. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1137, 121881 | 3.2 | 5 |
| 10 | The clinical pharmacology of the medical treatment for overactive bladder in adults. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 707-720 | 3.8 | 2 |
| 9 | Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1303-1313 | 2.5 | 0 |
| 8 | Current Pharmacologic Treatment of Lower Urinary Tract Symptoms. <i>Current Clinical Urology</i> , 2014 , 121-222 | | 1 |
| 7 | Pharmacologic Management of Lower Urinary Tract Storage and Emptying Failure. 2012 , 1967-2002.e14 | | 3 |
| 6 | Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding. <i>International Neurourology Journal</i> , 2012 , 16, 107-15 | 2.6 | 10 |
| 5 | Drug Treatment of Voiding Dysfunction in Women. 2010 , 418-446 | | |

4 The Bladder as a Dynamic System. **2013**, 1-23

3 Overactive Bladder (OAB) in the Elderly with Contemporary Notions on Treatment Including Sacral Nerve Stimulation (SNS). **2017**, 195-209

2 Individualizing Drug Therapy. **2019**, 291-314

1 Darifenacin: a selective M3muscarinic receptor antagonist for the treatment of overactive bladder. *Therapy: Open Access in Clinical Medicine*, **2006**, 3, 723-732